Lisa Kierstead

HIV-1 vaccine-induced immunity in the test-of-concept Step Study: a case–cohort analysis

M. Juliana McElrath, Stephen C. De Rosa, Zoe Moodie et al. · The Lancet · 2008 · 700 citations · Full text

Veterinary Medicine, Immunology, Infectious Diseases +14

Disease-associated Bias in T Helper Type 1 (Th1)/Th2 CD4<b>+</b> T Cell Responses Against MAGE-6 in HLA-DRB10401<b>+</b> Patients With Renal Cell Carcinoma or Melanoma

Tomohide Tatsumi, Lisa Kierstead, Elena Ranieri et al. · The Journal of Experimental Medicine · 2002 · 306 citations · Full text

Life Sciences, Immunology, Oncology +17

International epidemiology of human pre-existing adenovirus (Ad) type-5, type-6, type-26 and type-36 neutralizing antibodies: Correlates of high Ad5 titers and implications for potential HIV vaccine trials

T. Christopher Mast, Lisa Kierstead, Swati B. Gupta et al. · Vaccine · 2009 · 276 citations

Life Sciences, Immunology, Infectious Diseases +15

Safety and Immunogenicity of a Replication‐Incompetent Adenovirus Type 5 HIV‐1 Clade B<i>gag/pol/nef</i>Vaccine in Healthy Adults

Frances Priddy, Deborah D. Brown, James G. Kublin et al. · Clinical Infectious Diseases · 2008 · 247 citations · Full text

Veterinary Medicine, Immunology, Infectious Diseases +17

Melan-A/MART-1 _51–73 represents an immunogenic HLA-DR4-restricted epitope recognized by melanoma-reactive CD4 ⁺ T cells

Hassane M. Zarour, John M. Kirkwood, Lisa Kierstead et al. · Proceedings of the National Academy of Sciences · 2000 · 158 citations · Full text

Life Sciences, Immunology, Oncology +17